A Patient’s Journey Through HeFH: Diagnosis and Management
A Patient’s Journey Through HeFH: Diagnosis and Management is organized by Paradigm Medical Communications, LLC.
Release Date: 05-05-2023
Expire Date: 05-05-2024
Program Overview:
Nonstatins are an essential therapy for lowering low-density lipoprotein cholesterol (LDL-C) levels in high-risk patients, such as those with heterozygous familial hypercholesterolemia (HeFH). Join Dr. Soffer as he explores HeFH through this engaging drag-and-drop game of Operation.
Learning Objectives:
• Upon completion of this activity, participants should be able to:
• Distinguish among the unique drug characteristics of newer and emerging nonstatin LDL-C therapies that may impact clinical decision-making
• Formulate evidence-based treatment plans for patients who require additional LDL-C lowering beyond statin therapy, while engaging in shared decision-making to facilitate adherence